- Home
- PALI vs CNTX Comparison
PALI vs CNTX Comparison
Compare PALI & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | CNTX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.2M | 209.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PALI | CNTX |
|---|---|---|
| Price | $1.73 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $15.00 | $6.00 |
| AVG Volume (30 Days) | ★ 4.6M | 2.3M |
| Earning Date | 03-23-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.49 |
| 52 Week High | $2.64 | $2.85 |
Technical Indicators
Market Signals| Indicator | PALI | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 66.63 |
| Support Level | $1.65 | $2.09 |
| Resistance Level | $1.84 | $2.58 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 77.50 | 52.95 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.